Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8619293 | 1.00 | PYGL (0.63) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL6538568 | 0.79 | PYGL (0.63) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL6538415 | 0.79 | PYGL (0.63) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL8152014 | 0.78 | PYGL (0.55) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL7033031 | 0.78 | PYGL (0.55) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL1814865 | 0.77 | PYGL (0.61) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL8332561 | 0.77 | PYGL (0.61) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL6401981 | 0.74 | PYGL (0.51) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL27498579 | 0.73 | PYGL (0.56) | PYGLKDM4EGMNNLMNAMAPT | |
| SCHEMBL27477962 | 0.73 | PYGL (0.34) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
| EP-0599987-A4 | METHOD FOR LOWERING BLOOD LIPID LEVELS. | GENSIA INC (US) | 1995-02-01 | — | — | EP | disclosed |
| EP-0599987-A1 | METHOD FOR LOWERING BLOOD LIPID LEVELS | GENSIA, INC. (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993003734-A1 | METHOD FOR LOWERING BLOOD LIPID LEVELS | GENSIA, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | NSUN2, DUT, TYMP | PYGL 1365/4885KDM4E 2196/4885GMNN 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.